Atrial fibrosis is a hallmark of structural remodeling in atrial fibrillation (AF). Plasma procollagen type III N-terminal propeptide (PIIINP) reflects collagen synthesis and degradation while collagen type I carboxy-terminal telopeptide (ICTP) reflects collagen degradation. We aimed to study baseline plasma PIIINP and ICTP and their associations with incident AF in participants initially free of overt cardiovascular disease.
I
n 2010, the US prevalence of atrial fibrillation (AF) was 6.1 million and is expected to rise to at least 12.1 million by 2050.
1,2 AF is associated with significant morbidity and mortality. [3] [4] [5] [6] Cardiac fibrosis is thought to play a central role in the pathogenesis of AF. 7 Development and progression of atrial fibrosis are hallmarks of structural remodeling in AF and considered the substrate of AF perpetuation. 8 Type I and III collagens are the major collagens in both normal and diseased tissue. Two major biomarkers of collagen metabolism, procollagen type III N-terminal propeptide (PIIINP) and collagen type I carboxy-terminal telopeptide (ICTP), reflect collagen synthesis and degradation and degradation only, respectively. 9 AF is common in subjects with symptomatic and clinically recognizable inflammation conditions. Low-grade, asymptomatic inflammation may also contribute to the pathogenesis of AF. [10] [11] [12] [13] Processes of inflammation and pathological fibrosis are often intertwined. 14 Retrospective studies have suggested that circulating fibrosis biomarkers are associated with AF, but prospective studies are limited. In the Cardiovascular Health Study, a prospective cohort study of elderly men and women in which levels of plasma PIIINP were assessed in 2935 participants, 767 developed AF during 9 years follow-up. Risk of incident AF generally increased with PIIINP, with a nonsignificant tendency to flatten at higher PIIINP levels. 15 ICTP was not studied in CHS (the Cardiovascular Health Study). In the Atherosclerosis Risk in Communities study, the relationships between matrix metalloproteinases 1, 2, and 9, tissue inhibitor matrix metalloproteinase 1, 2, and C-terminal propeptide of collagen type-I with incident AF were examined after adjusting for confounders. 16 In models adjusted for age, sex, and race, all biomarkers were associated with AF, but only the relationship between plasma matrix metalloproteinase-9 remained significant in the fully-adjusted model.
The predictive value of collagen biomarkers for AF is largely unknown in subjects free of clinically recognized cardiovascular disease (CVD). Studying such persons affords the opportunity to examine the contribution of fibrosis to AF before the fibrosis can be the result of clinically overt CVD. It also offers advantages for determining the directionality of the fibrosis AF relationship because people free of CVD would be less likely to have clinically unrecognized AF at baseline, which could itself drive atrial mechanical remodeling and consequent fibrosis. Therefore, our hypothesis was that PIIINP and ICTP are positively associated with incidence of AF in middle-aged to older adults free of prevalent, clinically apparent CVD. Understanding associations between these collagen biomarkers and incident AF will suggest potential mechanisms of disease and may help in development of prevention strategies.
METHODS

Study Population
The MESA (Multi-Ethnic Study of Atherosclerosis) was initiated to investigate the prevalence, correlates, and progression of subclinical CVD in people initially free of overt clinical CVD, radiation or chemotherapy-treated cancer, other serious major illness, or cognitive impairment in the judgment of the screening interviewer before baseline. 17 Between 2000 and 2002, 6814 men and women of white, black, Hispanic, or Chinese race/ethnicity, aged 45 to 84 years were enrolled. The institutional review boards at all participating centers approved the study, and all participants signed informed consent. Following standard MESA procedures for data availability, the data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure after submission of a request to the MESA Publications and Presentations Committee (https:// mesa-nhlbi.org/Publications.aspx) and obtaining that committee's approval.
In the present stratified design, we excluded 1000 randomly selected MESA participants whose blood sample inventory had been depleted in earlier studies, as well as those who were missing baseline continuous blood pressure (BP) waveform measurement (the latter based on the original purpose of the design). We included 3071 participants, namely, all with any adjudicated CVD event (coronary heart disease, stroke, peripheral vascular disease, or heart failure) before 2011 plus a 56% random sample of all remaining participants (who had not had a CVD event through 2011). With random sampling and case weighting, our data analyses are representative of all of MESA although with somewhat expanded SEs of our estimates. All included participants had assessment of both PIIINP and ICTP at baseline.
Height and weight were measured in the MESA clinic, and body mass index (BMI) was defined as weight/height 2 (kg/m 2 ). Questionnaires were administered to ascertain sex,
WHAT IS KNOWN?
• Collagen biomarkers in the circulation are fragments of collagen molecules that arise from collagen activity throughout the body, including both normal tissue maintenance and repair. • Some atrial fibrillation is known to be associated with fibrosis in the atria.
WHAT THE STUDY ADDS?
• 18 In the PIIINP assay, a known amount of labeled PIIINP and an unknown amount of unlabeled PIIINP in the sample compete for the limited number of high affinity binding sites of the antibody. After separating the free antigen, the amount of labeled PIIINP in the sample tube is inversely proportional to the amount of PIIINP in the sample. The description of the ICTP assay is parallel to that for PIIINP, using an ICTP specific antibody. The concentrations in unknown samples are obtained from a calibration curve. Coefficients of variation for internal quality control samples during the main runs were 9.3% for PIIINP high control, 16.5% for PIIINP low control, 6.3% for ICTP high control, and 8.8% for ICTP low control.
Inflammatory Markers
hs-CRP (high sensitivity C-reactive protein) was measured using the BNII nephelometer (Dade Behring Inc, Deerfield, IL). Intra-assay and interassay analytic coefficient of variance ranged from 2.3% to 4.4% and 2.1% to 5.7%, respectively. IL-6 (interleukin 6) was measured by ultrasensitive ELISA (Quantikine HS Human IL-6 Immunoassay, R&D Systems, Minneapolis, MN). The laboratory analytic coefficient of variance for this assay was 6.3%. D-dimer was measured using an immunoturbidimetric assay on a Sta-R analyzer (Liatest D-DI, Diagnostica Stago, Parsippany, NJ). The lower limit of detection was 0.01 μg/mL. Intra assay coefficient of variance for D-dimer was 12.2% and interassay coefficient of variance range, 5% to 14%. The nuclear magnetic resonance (NMR) measurement of GlycA and the lipoprotein particles in the MESA study have been described in our previous publication. 19, 20 NMR spectra used were those acquired for NMR LipoProfile testing at the CLIA-certified LipoScience (now LabCorp) clinical laboratory in Raleigh, NC. GlycA is a composite of α-glycoprotein inflammatory markers; its chemical origins and its analytic and biological variabilities have been described in detail. 19 Reported coefficients of variation for intra-and interassay precision were 1.9% and 2.6%, respectively. The sum of small plus medium HDL particles, which we have shown to have anti-inflammatory properties, had coefficients of variation of 9% (small HDL particles) and 14% (medium HDL particles). 
Statistical Analysis
All analyses were weighted inversely to the sampling weight (1 or 0.56, in effect treating each participant who did not have a CVD event before 2011 as representing 1/0.56=1.79 participants). Mean and SD or counts and percentages were calculated for description. We initially performed Poisson regression with follow-up time offset predicting new onset of AF from PIIINP and ICTP, both as continuous variables. We also examined the data across equal concentration interval categories of PIIINP and ICTP (categories specified in the tables, lowest and highest categories are open-ended) as a way to display the shapes of the associations with the outcomes. Because the analyses of the equal interval categories strongly suggested threshold associations of the collagen biomarkers with incident AF, we report the associations in categories, with the lowest collagen biomarker levels as the reference, plus the P value for linear trend from the continuous models. The cut points were selected based on boundaries of the equal interval biomarker category variable. We also examined spline plots (data not shown), which agree with our visual judgments. In this way, we regard the continuous models only as general tests of upward trend and do not report linear slopes. The minimal model included age, race/ethnicity, and sex as covariates. The risk factor model added covariates height, heart rate, systolic and diastolic BPs, BP-lowering medications, BMI, former and current smoking, diabetes mellitus, total cholesterol, HDL cholesterol, triglycerides, cholesterollowering medication, clinic, estimated glomerular filtration rate (eGFR) and low eGFR (<60 mL/min per 1.73 m 2 ), hs-CRP, interleukin 6, D-dimer, GlycA, and small plus medium HDL particles. (The propriety of inclusion of height and BMI in the same model is discussed in the Methodological Note in the Data Supplement.) After backwards elimination, several variables were not associated with AF, and the risk factor model shown in the tables included only systolic BP, height, BMI, current smoking, and low eGFR. We recognize that age, renal status, and some risk variables may be causally linked to fibrosis as indicated by collagen biomarkers. To the extent that they are causally linked to fibrosis, we may be adjusting for mediating factors and therefore underestimating the strength of association. In sensitivity analyses, we used the random sample of cohort participants without weighting and using Cox proportional hazards regression. These analyses yielded similar conclusions, with the estimated associations in the Cox models slightly stronger than in the Poisson models (data not shown). The advantage of the Poisson models is that they give direct estimates of the absolute incidence densities. At the suggestion of a reviewer, we examined AF with or without incident CVD during follow-up, according to whether the incident CVD occurred before, with (30 days before or after), or after AF diagnosis. In this exploratory analysis, we identified AF without incident CVD at least until 30 days after AF diagnosis and compared that to AF that was accompanied by CVD before or with AF diagnosis. For the AF without incident CVD, we computed continuous net reclassification improvement to compare models with covariates only to models that included a collagen biomarker. We considered P<0.05 to be noteworthy in general screening of findings. Analyses were performed using PC-SAS version 9.4 (SAS institute, Cary, NC). Table 1 and Table I in the Data Supplement summarize the baseline characteristics according to PIIINP and to ICTP equal concentration interval categories. The mean age increased monotonically across all categories of ICTP and from the first category of PIIINP through the 7 µg/L category. There were small differences in ethnic distribution among the PIIINP categories while Chinese were less likely to have high ICTP. Although there was no significant difference for systolic and diastolic BPs among the categories, there was an increase in height, heart rate, BMI, and antihypertensive medication use with higher PIIINP and ICTP levels. Total cholesterol and HDL cholesterol were lower in the higher PIIINP and ICTP levels. There was no difference in diabetes mellitus. Renal function was lower with higher PIIINP and ICTP levels. Hs-CRP, interleukin 6, and D-dimer were higher with higher PIIINP and ICTP levels. Small and medium HDL particles were lower with higher PIIINP and ICTP. Both current smoking and GlycA were inversely associated with PIIINP although smoking was unrelated to ICTP and GlycA had a nomonotonic, but generally positive association with ICTP. ICTP and PIIINP had a correlation coefficient of 0.4. Table 2 shows the mean ICTP and PIIINP concentrations according to AF with or without accompanying CVD. The incident disease subgroups with consistently high collagen markers were the 166 people with incident AF without any incident CVD event and the 61 people with incident AF who did subsequently have an incident CVD event but not until at least 30 days after the diagnosis of AF.
RESULTS
Incident AF during the 10-year follow-up was identified in 357 participants. The Figure summarizes the AF incidence density for each category of each collagen biomarker. Positive linear trend was significant in each model (Tables 3 and 4) . Threshold relationships were suggested visually in the Figure, with small gradual increase across the lower categories, particularly in the demographic-adjusted model. The apparent threshold for PIIINP was at 8.5 µg/L (3.5% of the sample), with relative incidence density (RID) 2.81 (1.94-4.08) in the demographic-adjusted model and 2.29 (1.57-3.34) in the more adjusted model. Correspondingly for ICTP, the apparent threshold was at 7 µg/L (1.7% of the sample), with RID 3.46 (2.36-5.07) in the demographic-adjusted model and 2.44 (1.60-3.72) in the more adjusted model. Associations of ICTP and PIIINP with incident AF not accompanied by incident CVD event (n=227) were stronger than those for total AF. Net reclassification improvement is ≈0.14 (P<0.003) for both markers. We also note that the adjusted incidence density rates in those for whom the addition of the collagen markers suggested a higher risk versus a lower risk were 7.8 versus 5.8 per 1000 person-years (P=0.003) for ICTP and 8.2 versus 5.6 per hundred person-years (P<0.0001) for PIIINP. The collagen markers were not related to incident stroke (data not shown).
Other demographic variables and risk factors in the more adjusted model were associated with incident AF, including age (RID per year, 1.10; 95% CI, 1.08-1.11), black and Hispanic race/ethnicity (lower risk than whites or Chinese), height (RID per cm, 1.04; 95% CI, 1.02-1.05), systolic BP (RID per 10 mm Hg, 1.08; 95% CI, 1.04-1.13), BMI (RID per kg/m 2 , 1.05; 95% CI, 1.03-1.07), and current smoking (RID versus never smoker, 1.46; 95% CI, 1.07-1.98). Low eGFR<60 mL/ min per 1.73 m 2 was correlated with incident AF when adjusted for PIIINP (RID versus higher eGFR, 1.48; 95% CI, 1.13-1.94) but was not significant when adjusted for ICTP. Other risk factor and inflammatory variables were at most weakly associated with future AF.
DISCUSSION
Our main and novel findings were that in a large multiethnic and middle-aged sample, initially free of clinically recognized CVD, the collagen biomarkers PIIINP and ICTP predicted new onset of AF during a median followup of ≈10 years. The shape of relationship was generally increasing, with apparent thresholds >8.5 µg/L for PIIINP and >7 µg/L for ICTP. The strong effect sizes in the highest categories of PIIINP and ICTP fit well with 2 earlier reports. Collagen biomarkers were strongly related to total death and chronic inflammatory-related severe hospitalization and death. 18 For the less frequently occurring outcome heart failure with preserved ejection fraction, a threshold association was found in the relationship of PIIINP 21 as we report here for AF. Circulating collagen biomarkers should be interpreted with consideration of their meaning in relation to collagen molecules systemically. Collagen biomarkers that are found in the circulation are fragments of collagen molecules that arise from collagen activity throughout the body, including both normal tissue maintenance and tissue repair. Therefore, circulating collagen biomarkers are an imperfect measure of tissue repair. At any one time, several organs may be undergoing tissue repair with attendant collagen molecule production. In this case, epidemiological disease associations would be consistent for broad ranges of PIIINP and ICTP. If only one organ was undergoing tissue repair at the time of plasma collagen biomarker measurement, only a small portion of the variation in plasma collagen biomarker would be expected from that organ repair. Then, epidemiologically, a threshold would be expected.
We explored subsets of AF. We found that the subset of AF which was not associated with incident CVD at all during MESA follow-up or until at least 30 days after AF diagnosis was strongly associated with the collagen biomarkers, in contrast with AF which was associated with CVD either diagnosed before or concurrent with AF. These findings are suggestive that fibrosis is a cause of AF when CVD is not present, but AF may also be responsive to other features of CVD in those who have AF accompanied by CVD. Results are given either in percentage (%) or as mean±SD. Equal concentration interval categories of PIIINP and ICTP were used (note that lowest and highest categories are open-ended).
*eGFR: Estimated glomerular filtration rate mL/min per 1.73 m 2 based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula using serum creatinine.
There is limited information in the literature on the predictive value of PIIINP and ICTP for AF in study participants without clinically recognized CVD at baseline. In the Cardiovascular Health Study, PIIINP was measured in 2935 participants, and the risk of incident AF was studied for a median follow-up of 8.8 years. 15 AF was identified based on an annual resting ECG through the ninth year of follow-up and discharge diagnoses for all hospitalizations based on the International Classification of Diseases codes. The Cardiovascular Health Study sample was older (mean age range, 77-78 years) than the MESA study sample. More than 50% of the participants were treated for hypertension. In contrast to our study, some participants in the Cardiovascular Health Study had a history of heart failure, myocardial infarction, or stroke. In that study, they found a linear relationship between the risk of AF and PIIINP approximately up to the median value both before and after adjustment for demographics, CVD risk factors, and history of heart failure and stroke. Above the median value of PIIINP, the association between PIIINP and AF risk was not significant while in our MESA study, only the highest category of PIIINP and ICTP levels were predictive for AF.
Fibrosis is a process of normal repair that is activated in response to injury to maintain the original tissue architecture and functional integrity. Prolonged chronic injurious stimuli may cause deregulation of normal processes and result in an excess deposition of extra- Covariates are set to their overall means in the plotted points. Further adjustment for heart rate, diastolic blood pressure, blood pressure-lowering medications, former smoking, diabetes mellitus, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, cholesterol-lowering medication, high sensitivity C-reactive protein, interleukin 6, D-dimer, GlycA, and small plus medium HDL particles did not substantially alter the estimates and is not shown. cellular matrix and fibrosis. Fibrosis involves complex multistage inflammatory processes with inflammatory cell and extracellular matrix expansion, where numerous factors, including cytokines/chemokines, growth factors, adhesion molecules, and signaling processes, play a role. 10, 14, 22, 23 Several hypotheses for our findings may be formulated. [22] [23] [24] In the presence of risk factors like obesity, obstructive sleep apnea, and diabetes mellitus, inflammation and an increased sympathetic tone may play a pathological role for AF. Moreover, an important concept is that inflammation contributes to AF before there is consolidation of the inflammatory process leading to structural changes and fibrosis. 25 However, we reported here that 5 inflammatory markers did not predict future AF; perhaps, such inflammatory factors become important more proximally to the emergence of AF. The molecular basis for the heritability of AF has been explored in depth during the past decade. Rare variants have been identified in ion channels, transcription factors, and a wide range of other genes. 26 As with other epidemiological studies, the ascertainment and classification of AF is a potential limitation of the present study. Because we had access to hospital discharge diagnoses through MESA cardiovascular events surveillance, plus Medicare outpatient and inpatient claims, our ascertainment may be relatively good. 27 However, we are aware that paroxysmal AF may go unrecognized by the patient and not occur at a clinic visit. Therefore, the true AF prevalence is likely to be higher. The type of AF, whether symptomatic or asymptomatic (paroxysmal, persistent, or chronic), cannot be discriminated in this study. A cause-effect relationship cannot be firmly established. It is possible that residual confounding might explain the prediction of new cases of AF by low level collagen biomarkers. Statistically, detecting and describing nonlinear relationships is inherently much more challenging than finding linear associations.
In conclusion, our results add further insight on collagen biomarkers and AF. Collagen biomarkers were associated with incident AF in an increasing fashion, with an apparent threshold in asymptomatic subjects free of overt CVD.
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